Cargando…

Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network

BACKGROUND: Butyrate acts as a regulator in multiple inflammatory organ injuries. However, the role of butyrate in acute liver injury has not yet been fully explored. In the present study, we aimed to investigate the association between butyrate and lipopolysaccharide (LPS)-induced acute liver injur...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Qian-Jiang, Sun, Mei-Xing, Guo, Yun-Wei, Tan, Si-Wei, Wu, Xiao-Ying, Abassa, Kodjo-Kunale, Lin, Li, Liu, Hui-Ling, Jiang, Jie, Wei, Xiu-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128024/
https://www.ncbi.nlm.nih.gov/pubmed/34026223
http://dx.doi.org/10.1093/gastro/goaa085
_version_ 1783694045872128000
author Luo, Qian-Jiang
Sun, Mei-Xing
Guo, Yun-Wei
Tan, Si-Wei
Wu, Xiao-Ying
Abassa, Kodjo-Kunale
Lin, Li
Liu, Hui-Ling
Jiang, Jie
Wei, Xiu-Qing
author_facet Luo, Qian-Jiang
Sun, Mei-Xing
Guo, Yun-Wei
Tan, Si-Wei
Wu, Xiao-Ying
Abassa, Kodjo-Kunale
Lin, Li
Liu, Hui-Ling
Jiang, Jie
Wei, Xiu-Qing
author_sort Luo, Qian-Jiang
collection PubMed
description BACKGROUND: Butyrate acts as a regulator in multiple inflammatory organ injuries. However, the role of butyrate in acute liver injury has not yet been fully explored. In the present study, we aimed to investigate the association between butyrate and lipopolysaccharide (LPS)-induced acute liver injury and the signaling pathways involved. METHODS: LPS-induced acute liver injury was induced by intraperitoneal injection of LPS (5 mg/kg) in G-protein-coupled receptor 43 (GPR43)-knockout (KO) and wild-type female C57BL/6 mice. Sodium butyrate (500mg/kg) was administered intraperitoneally 30 min prior to LPS exposure. Liver injury was detected by serum markers, tissue morphology, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). Pro-inflammatory-factor levels were detected by enzyme-linked immunosorbent assay and real-time polymerase chain reaction (RT-PCR). Cell models were first treated with sodium butyrate (4 μmol/mL), followed by LPS (1 μg/mL) half an hour later in GPR43 small interfering RNA (siRNA)-transfected or control RAW264.7 cells. Cell-inflammation status was evaluated through detecting pro-inflammatory-factor expression by RT-PCR and also through checking toll-like receptor 4/nuclear factor-κB (TLR4/NF-κB)-element levels including TLR4, TRAF6, IKKβ, IкBα, phospho-IкBα, p65, and phospho-p65 by Western blot. The interaction between GPR43 and β-arrestin-2 was tested by co-immunoprecipitation. RESULTS: Sodium butyrate reversed the LPS-induced tissue-morphology changes and high levels of serum alanine aminotransferase, aspartate transaminase, myeloperoxidase, TUNEL, and pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-6. The ameliorating effect of sodium butyrate was weakened in GPR43-KO mice and GPR43 siRNA RAW264.7 cells, compared with those of GPR43-positive controls. Sodium butyrate downregulated some elements of the TLR4/NF-κB pathway, including phospho-IκBα and phospho-p65, in RAW264.7 cells. Increased interactions between GPR43 and β-arrestin-2, and between β-arrestin-2 and IкBα were observed. CONCLUSION: Sodium butyrate significantly attenuated LPS-induced liver injury by reducing the inflammatory response partially via the GPR43/β-arrestin-2/NF-κB signaling pathway.
format Online
Article
Text
id pubmed-8128024
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-81280242021-05-20 Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network Luo, Qian-Jiang Sun, Mei-Xing Guo, Yun-Wei Tan, Si-Wei Wu, Xiao-Ying Abassa, Kodjo-Kunale Lin, Li Liu, Hui-Ling Jiang, Jie Wei, Xiu-Qing Gastroenterol Rep (Oxf) Original Articles BACKGROUND: Butyrate acts as a regulator in multiple inflammatory organ injuries. However, the role of butyrate in acute liver injury has not yet been fully explored. In the present study, we aimed to investigate the association between butyrate and lipopolysaccharide (LPS)-induced acute liver injury and the signaling pathways involved. METHODS: LPS-induced acute liver injury was induced by intraperitoneal injection of LPS (5 mg/kg) in G-protein-coupled receptor 43 (GPR43)-knockout (KO) and wild-type female C57BL/6 mice. Sodium butyrate (500mg/kg) was administered intraperitoneally 30 min prior to LPS exposure. Liver injury was detected by serum markers, tissue morphology, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). Pro-inflammatory-factor levels were detected by enzyme-linked immunosorbent assay and real-time polymerase chain reaction (RT-PCR). Cell models were first treated with sodium butyrate (4 μmol/mL), followed by LPS (1 μg/mL) half an hour later in GPR43 small interfering RNA (siRNA)-transfected or control RAW264.7 cells. Cell-inflammation status was evaluated through detecting pro-inflammatory-factor expression by RT-PCR and also through checking toll-like receptor 4/nuclear factor-κB (TLR4/NF-κB)-element levels including TLR4, TRAF6, IKKβ, IкBα, phospho-IкBα, p65, and phospho-p65 by Western blot. The interaction between GPR43 and β-arrestin-2 was tested by co-immunoprecipitation. RESULTS: Sodium butyrate reversed the LPS-induced tissue-morphology changes and high levels of serum alanine aminotransferase, aspartate transaminase, myeloperoxidase, TUNEL, and pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-6. The ameliorating effect of sodium butyrate was weakened in GPR43-KO mice and GPR43 siRNA RAW264.7 cells, compared with those of GPR43-positive controls. Sodium butyrate downregulated some elements of the TLR4/NF-κB pathway, including phospho-IκBα and phospho-p65, in RAW264.7 cells. Increased interactions between GPR43 and β-arrestin-2, and between β-arrestin-2 and IкBα were observed. CONCLUSION: Sodium butyrate significantly attenuated LPS-induced liver injury by reducing the inflammatory response partially via the GPR43/β-arrestin-2/NF-κB signaling pathway. Oxford University Press 2020-11-22 /pmc/articles/PMC8128024/ /pubmed/34026223 http://dx.doi.org/10.1093/gastro/goaa085 Text en © The Author(s) 2020. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Luo, Qian-Jiang
Sun, Mei-Xing
Guo, Yun-Wei
Tan, Si-Wei
Wu, Xiao-Ying
Abassa, Kodjo-Kunale
Lin, Li
Liu, Hui-Ling
Jiang, Jie
Wei, Xiu-Qing
Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network
title Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network
title_full Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network
title_fullStr Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network
title_full_unstemmed Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network
title_short Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43/ β-arrestin-2/NF-κB network
title_sort sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the gpr43/ β-arrestin-2/nf-κb network
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128024/
https://www.ncbi.nlm.nih.gov/pubmed/34026223
http://dx.doi.org/10.1093/gastro/goaa085
work_keys_str_mv AT luoqianjiang sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT sunmeixing sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT guoyunwei sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT tansiwei sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT wuxiaoying sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT abassakodjokunale sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT linli sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT liuhuiling sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT jiangjie sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork
AT weixiuqing sodiumbutyrateprotectsagainstlipopolysaccharideinducedliverinjurypartiallyviathegpr43barrestin2nfkbnetwork